Dieter Zopf

Berlin, BE 13342, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Inhibition of EphB4 Receptor Signaling by Ephrin-B2-Competitive and Non-Competitive DARPins Prevents Angiogenesis.

Inhibition of EphB4 Receptor Signaling by Ephrin-B2-Competitive and Non-Competitive DARPins Prevents Angiogenesis.

Journal: Biochemistry

Published: January 17, 2025

Correction: Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice.

Correction: Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice.

Journal: European journal of medical research

Published: June 24, 2023

A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.

A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.

Journal: Molecular cancer therapeutics

Published: January 18, 2023

Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice.

Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice.

Journal: European journal of medical research

Published: September 13, 2022

T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction.

T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction.

Journal: Oncoimmunology

Published: February 10, 2022

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth.

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 05, 2021

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.

Journal: Journal for immunotherapy of cancer

Published: October 27, 2020

Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.

Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.

Journal: Cancer medicine

Published: July 20, 2019

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Journal: International journal of cancer

Published: September 07, 2018

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma.

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma.

Journal: Oncotarget

Published: June 08, 2017

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.

Journal: Cancer medicine

Published: April 07, 2016

Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.

Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 06, 2015

Showing 1-12 of 16

Last Updated: 09/26/2026